Čájehuvvojit 1 - 5 oktiibuot 5 bohtosis ohcui Seyed Reza Mousavi (13223324)', ohcanáigi: 0,01s Aiddostahte ozu
  1. 1
    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites.

    The non-inferiority margin in Phase III clinical trial of SnaFab compared to Razi antivenom in snakebites. Dahkki Seyed Reza Mousavi (13223324)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58].

    Snakebite severity classification in clinical trial of SnaFab vs. Razi antivenom in snakebite victims [14,57,58]. Dahkki Seyed Reza Mousavi (13223324)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites.

    Adverse events during follow-up period in Phase III non-inferiority clinical trial of SnaFab compared to Razi antivenom in snakebites. Dahkki Seyed Reza Mousavi (13223324)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Consort Chart of Phase III clinical trial of SnaFab compare to Razi antivenom in snakebites. Dahkki Seyed Reza Mousavi (13223324)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites.

    Demographic information and clinical presentation of victims in Phase III non-inferiority clinical trial of SnaFab compare to Razi antivenom in snakebites. Dahkki Seyed Reza Mousavi (13223324)

    Almmustuhtton 2025
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: